Loading clinical trials...
Loading clinical trials...
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.
Conditions
Interventions
Fenebrutinib
Ocrelizumab
+2 more
Locations
189
United States
Alabama Neurology Associates
Homewood, Alabama, United States
Sutter East Bay Medical Foundation
Berkeley, California, United States
Fullerton Neurology and Headache Center
Fullerton, California, United States
Palo Alto Medical Foundation Research Center
Sunnyvale, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Yale University School Of Medicine
Fairfield, Connecticut, United States
Start Date
October 26, 2020
Primary Completion Date
September 17, 2025
Completion Date
July 21, 2027
Last Updated
March 27, 2026
NCT05359653
NCT06138132
NCT03455582
NCT04918225
NCT05663853
NCT05496881
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions